CBCA Holds that Contractor is Out on a Limb Seeking Claim Preparation Costs, but Grants T4C Partial Victory
Client Alert | 1 min read | 02.11.19
In Woolery Timber Management, Inc. v. Department of Agriculture (CBCA No. 6031), the contractor sought damages for the alleged partial termination of its contract and various other costs, including consulting fees related to the contractor’s preparation of its certified claim and extra time expended as a result of blocked access to a road. With respect to the alleged partial termination, the Board found that it was not, in fact, a termination at all because the parties failed to execute a draft bilateral modification that would have eliminated some work scope, and the contracting officer never unilaterally issued the modification. However, the Board noted that, earlier, the CO had partially terminated for convenience, but that the contractor failed to submit a termination settlement proposal within one year of that earlier termination. That failure was not fatal. The Board explained that because the earlier termination occurred under the commercial items termination for convenience clause (FAR 52.212-4), and not the FAR’s standard termination for convenience clause, there was no one-year time limit and, thus, Woolery still could “pursue a remedy for any increased costs resulting from the…convenience termination.” Regarding Woolery’s cost claims, the Board reiterated that, consistent with Bill Strong, Woolery could not recover its claim preparation costs. Lastly, the Board awarded Woolery half of its idle equipment damages resulting from a service road that was accidentally blocked — despite the fact that the solicitation did not warrant that Woolery could use the road (generally, this language is required to make an excusable delay compensable).
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection


